Filing Flows › Health Care › BridgeBio Pharma (BBIO)
BridgeBio Pharma (BBIO) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · BridgeBio Pharma (BBIO) Q3 2026 earnings results →
Q3 2026 Revenue up 193% year over year to $353M · 17¢ of every $1 of revenue lost · operating margin -3.3%
BridgeBio Pharma made $353M in Q3 2026 (+193% Y/Y): Net product revenue $253M, License and services revenue $79.3M, Royalty revenue $20.5M. Operating margin -3.3%, net loss $60.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $353.2M in Q3 2026, up 193% year over year and up 45% from the previous quarter. Net product revenue was the largest line at 72% of revenue. Net product revenue added $145.2M year over year (up 134%), 62% of the total change.
Operating costs exceeded revenue by $11.6M, an operating margin of -3.3%. Total costs grew 37% against revenue growth of 193%. The fastest-growing cost line was Cost of revenue (+212%). The quarter ended with a net loss of $60.5M, narrower than the previous quarter's $155.9M loss. Minority interests bore $3.8M of it: to shareholders the quarter was a loss of $56.7M. Net interest and other expense of $47.6M was the main reason.
Operating cash flow was −$44.2M. Non-cash charges added back $1.1M of depreciation and amortization and $39.9M of share-based compensation. Working capital and other items used $24.6M. Capital expenditures of $290K exceeded it, leaving free cash flow of −$44.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 29, 2026 | $353M | +193% | -3.3% | −$60.5M | −$44.2M |
| Q2 2026 | 10-Q | Aug 10, 2026 | $244M | +120% | -43.9% | −$156M | −$71.1M |
| Q1 2026 | 10-Q | May 7, 2026 | $195M | +67% | -54.5% | −$167M | −$197M |
| Q4 2025 | 10-K | Feb 24, 2026 | $154M | 26× | -90.5% | −$195M | −$56.4M |
| Q3 2025 | 10-Q | Oct 29, 2025 | $121M | 44× | -120.3% | −$185M | −$110M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $111M | 51× | -121.4% | −$184M | −$80.7M |
| Q1 2025 | 10-Q | Apr 29, 2025 | $117M | -45% | -89.5% | −$170M | −$199M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About BridgeBio Pharma
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with our approved medicines, and we have obtained U.S. Food and Drug Administration (the “FDA”) approval for three products.
In its own words, from its 10-K, filed Feb 24, 2026.
BridgeBio Pharma against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +193% against the peers' median +10%. Operating margin: -3.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BBIO BridgeBio Pharma | Q3 2026 | $353M | +193% | -3.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: BridgeBio Pharma 10-Q on SEC EDGAR · CIK 1743881 · Pharmaceutical Preparations
13F: who owns BBIO and who is buying
More on BBIO
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results